TW202242090A - 具減少脂肪與提升運動表現的乳酸菌組合物及其用途 - Google Patents
具減少脂肪與提升運動表現的乳酸菌組合物及其用途 Download PDFInfo
- Publication number
- TW202242090A TW202242090A TW110119591A TW110119591A TW202242090A TW 202242090 A TW202242090 A TW 202242090A TW 110119591 A TW110119591 A TW 110119591A TW 110119591 A TW110119591 A TW 110119591A TW 202242090 A TW202242090 A TW 202242090A
- Authority
- TW
- Taiwan
- Prior art keywords
- strain
- composition
- lactic acid
- acid bacteria
- food
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 241000894006 Bacteria Species 0.000 title claims abstract description 36
- 239000004310 lactic acid Substances 0.000 title claims abstract description 30
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 30
- 230000001737 promoting effect Effects 0.000 title 1
- 235000013305 food Nutrition 0.000 claims abstract description 33
- 239000003085 diluting agent Substances 0.000 claims abstract description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 7
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 7
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 7
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 6
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 6
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 6
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 6
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 6
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 5
- 238000011161 development Methods 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 230000037078 sports performance Effects 0.000 claims description 8
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 7
- 235000019543 dairy drink Nutrition 0.000 claims description 7
- 239000006186 oral dosage form Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 5
- 244000057717 Streptococcus lactis Species 0.000 claims description 5
- 235000013351 cheese Nutrition 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000016213 coffee Nutrition 0.000 claims description 4
- 235000013353 coffee beverage Nutrition 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 235000015140 cultured milk Nutrition 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 235000013616 tea Nutrition 0.000 claims description 4
- 235000013618 yogurt Nutrition 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims 2
- 239000008267 milk Substances 0.000 claims 2
- 210000004080 milk Anatomy 0.000 claims 2
- 235000020124 milk-based beverage Nutrition 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 238000012827 research and development Methods 0.000 abstract 1
- 235000009200 high fat diet Nutrition 0.000 description 97
- 241000699670 Mus sp. Species 0.000 description 45
- 239000006041 probiotic Substances 0.000 description 32
- 235000018291 probiotics Nutrition 0.000 description 32
- 235000005911 diet Nutrition 0.000 description 24
- 230000037213 diet Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 230000000529 probiotic effect Effects 0.000 description 15
- 235000021590 normal diet Nutrition 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 210000000577 adipose tissue Anatomy 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 230000009469 supplementation Effects 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 8
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 8
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 8
- 239000005642 Oleic acid Substances 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000003194 forelimb Anatomy 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 102000016938 Catalase Human genes 0.000 description 4
- 108010053835 Catalase Proteins 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000037080 exercise endurance Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000028070 sporulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- -1 cyclopropene fatty acid Chemical class 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/245—Lactobacillus casei
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本發明提供一種乳酸菌組合物,其包含植物乳桿菌
Lactobacillus plantarumPL-02菌株(寄存編號:BCRC 911012)、嗜酸乳酸桿菌
Lactobacillus acidophilusTYCA06菌株(寄存編號:BCRC 910813)、乾酪乳酸桿菌
Lactobacillus caseiCS-773菌株(寄存編號:BCRC 910534)、以及生理上可接受的賦形劑、稀釋劑或載體,上述菌株寄存於財團法人食品工業發展研究所生物資源保存及研究中心。
Description
本申請案主張2021年4月28日提申之中國大陸發明專利申請號第202110467618.9號申請案衍生的優先權,其整體內容併於此處以供參考。
本發明關於一種組合物,特別攸關一種具減少脂肪與提升運動表現的乳酸菌組合物。本發明另涵蓋上述乳酸菌組合物的用途。
肥胖為全球現代文明病,世界衛生組織(WHO)更警示「肥胖為一種慢性疾病」。依我國2017年十大死因調查,發現七項死因與肥胖有關。肥胖乃熱量攝取過多、消耗過少,導致熱量轉換成脂肪並於體內堆積所致。除了遺傳外,致胖環境與生活型態亦為造成肥胖的因子。於臨床營養上,常用身體質量指數(body mass index,BMI)或腰圍作為肥胖判斷指標;於我國,24≦BMI<27屬過重,27≦BMI<30屬輕度肥胖,30≦BMI<35屬中度肥胖,BMI≥35則屬重度肥胖。研究指出糖尿病、心血管疾病、代謝症候群、膽囊疾病、血脂異常、呼吸困難、睡眠呼吸停頓、及癌症等與過重或肥胖間有某種程度的關聯。研究另指出體重減少5%以上(如:90公斤成人減輕5公斤)則可為健康帶來許多助益,進而改善高血壓與糖尿病等疾病。研究又指出不當節食減重大多讓人減少肌肉,而非脂肪,如此反而影響健康。肌肉主要負責身體基礎代謝,肌肉減少易造成四肢無力、平衡變差而提高跌倒與骨折風險。
當餵食人體或動物益生菌時,可改善腸胃道菌叢品質,促進消化與健康。因此,益生菌對健康安全無虞,惟益生菌須作用於宿主,始能增進宿主健康。職是之故,尋找具促進身體減重、降低體脂肪與血脂,並提升肌肉力量與耐力等功能的乳酸菌菌株,並利用所尋找的菌株開發安全且可長期服用的營養補充品為目前亟需努力的課題之一。
本發明基於發現所提出之乳酸菌組合物可有效降低體重並降低體脂肪與血脂所完成的。另更發現所提出的組合物可使小鼠前肢抓力與跑步耐力表現皆優於市售品
Lactobacillus plantarumTWK10。
本發明之目的在於提供一種乳酸菌組合物,其可減重、提升人體運動能力並增強身體組成,以達到提升肌肉力量與耐力等功效。
是以,本發明提供一種乳酸菌組合物,其包含植物乳桿菌
Lactobacillus plantarumPL-02菌株(寄存編號:BCRC 911012)、嗜酸乳酸桿菌
Lactobacillus acidophilusTYCA06菌株(寄存編號:BCRC 910813)、乾酪乳酸桿菌
Lactobacillus caseiCS-773菌株(寄存編號:BCRC 910534)、以及生理上可接受的賦形劑、稀釋劑或載體,上述菌株寄存於財團法人食品工業發展研究所生物資源保存及研究中心。
較佳地,所述的乳酸菌組合物更包括:長雙歧桿菌嬰兒亞種
Bifidobacterium longum subsp. infantisBLI-02菌株(寄存編號:BCRC 910812)以及鼠李糖乳酸桿菌
Lactobacillus rhamnosusbv-77菌株(寄存編號:BCRC 910533),上述菌株寄存於財團法人食品工業發展研究所生物資源保存及研究中心。
較佳地,所述的乳酸菌組合物更包括:長雙歧桿菌嬰兒亞種
Bifidobacterium longum subsp. infantisBLI-02菌株(寄存編號:BCRC 910812)以及乳酸乳球菌
Lactococcus lactisLY-66菌株(寄存編號:BCRC 911055),上述菌株寄存於財團法人食品工業發展研究所生物資源保存及研究中心。
較佳地,所述的乳酸菌組合物為一食品組合物或一醫藥組合物。
較佳地,所述之生理上可接受的賦形劑、稀釋劑或載體為一食品,食品為乳製飲品、茶、咖啡、糖果或機能性飲品,乳製飲品為發酵乳、優格、乳酪或乳粉。
較佳地,所述的醫藥組合物呈口服劑型,而口服劑型為錠劑、膠囊、溶液劑或粉劑。
較佳地,所述之乳酸菌組合物的總菌株數量為10
6CFU以上。
本發明另提供一種上述乳酸菌組合物用於製備減少脂肪與提升運動表現之組合物的用途。
為讓本發明上述及/或其他目的、功效、特徵更明顯易懂,下文特舉較佳實施方式,作詳細說明如下:
本發明所述之乳酸菌菌株以冷凍乾燥培養物形式寄存於財團法人食品工業發展研究所生物資源保存及研究中心,地址為新竹市食品路331號,而寄存的詳細資料如下列表1所示:
表1、寄存資訊
菌株名 | 分類 | 寄存編號 | 寄存日期 |
PL-02 | 植物乳桿菌 Lactobacillus plantarum | BCRC 911012 | 2020年7月28日 |
TYCA06 | 嗜酸乳酸桿菌 Lactobacillus acidophilus | BCRC 910813 | 2018年1月18日 |
CS-773 | 乾酪乳酸桿菌 Lactobacillus casei | BCRC 910534 | 2011年12月27日 |
BLI-02 | 長雙歧桿菌嬰兒亞種 Bifidobacterium longum subsp. infantis | BCRC 910812 | 2018年1月18日 |
bv-77 | 鼠李糖乳酸桿菌 Lactobacillus rhamnosus | BCRC 910533 | 2011年12月27日 |
LY-66 | 乳酸乳球菌 Lactococcus lactis | BCRC 911055 | 2021年4月23日 |
本文發現如表1所列之寄存的PL-02菌株、TYCA06菌株、與CS-773菌株可減重、提升運動能力、與降低疲勞感,而BLI-02菌株與bv-77菌株可減重,BLI-02菌株與LY-66菌株可提升運動能力。
於一實施方式,本發明所提之用於減少脂肪與提升運動表現的組合物,其包含:(a)經分離的乳酸菌菌株,乳酸菌菌株包含植物乳桿菌
Lactobacillus plantarumPL-02菌株(寄存編號:BCRC 911012)、嗜酸乳酸桿菌
Lactobacillus acidophilusTYCA06菌株(寄存編號:BCRC 910813)、及乾酪乳酸桿菌
Lactobacillus caseiCS-773菌株(寄存編號:BCRC 910534)以及(b)生理上可接受的賦形劑、稀釋劑或載體。
此外,為進一步提升所提之組合物的減重效果,(a)經分離的乳酸菌菌株更包含:長雙歧桿菌嬰兒亞種
Bifidobacterium longum subsp. infantisBLI-02菌株(寄存編號:BCRC 910812)以及鼠李糖乳酸桿菌
Lactobacillus rhamnosusbv-77菌株(寄存編號:BCRC 910533)。
再者,為進一步提升所提之組合物的運動能力效果,(a)經分離的乳酸菌菌株更包含:長雙歧桿菌嬰兒亞種
Bifidobacterium longum subsp. infantisBLI-02菌株(寄存編號:BCRC 910812)以及乳酸乳球菌
Lactococcus lactisLY-66菌株(寄存編號:BCRC 911055)。
較佳地,生理上可接受的賦形劑、稀釋劑或載體為醫藥上可接受的賦形劑、稀釋劑或載體,藉此所提之組合物可作為一醫藥組合物使用。
較佳地,生理上可接受的賦形劑、稀釋劑或載體為食用上可接受的賦形劑、稀釋劑或載體,藉此所提之組合物可作為一食品組合物使用。
於作為醫藥組合物下,所提之組合物呈口服劑型,而口服劑型例如錠劑、膠囊、溶液劑、或粉劑。
於作為食品組合物下,生理上可接受的賦形劑、稀釋劑或載體可為一食品,食品例如乳製飲品、茶、咖啡、糖果或機能性飲品,乳製飲品例如發酵乳、優格、乳酪或乳粉。
較佳地,(a)經分離的乳酸菌菌株單獨為活性菌株或去活性菌株。此外,於作為食品組合物或醫藥組合物的條件下,其總菌株數量為10
6CFU以上;更佳地,總菌株數量為10
10CFU以上。
<實施例1:菌株形態及一般性質>
依16S rDNA序列分析與API細菌鑑定系統分析確認菌株的分類學特徵,所用的菌株於形態及一般性質特徵詳如下文表2所示。
表2、菌株形態及一般性質特徵
菌株 | 形態特徵 |
植物乳桿菌 Lactobacillus plantarum PL-02菌株 | (1)兼性厭氧菌,可於低或正常的氧氣濃度下生活。 (2)適合的生長溫度為10至45℃,最佳範圍則為30至35℃,但於接近冰點溫度仍能存活。 (3)最佳的生長酸鹼值範圍為pH3.5至4.2,耐鹽性為13至15%。 (4)外觀呈直線型桿狀,兩端以圓弧收尾;通常寬0.9至1.2mm,長3.0至8.0mm,並以單個、兩兩成對或多個短鏈形式排列存在。 |
嗜酸乳酸桿菌 Lactobacillus acidophilusTYCA06菌株 | (1)於MRS瓊脂生長呈短或稍長桿狀,兩端呈方形,通常單獨或呈短鏈狀成對出現。 (2)革蘭氏染色陽性桿菌,不生成孢子,不具觸酶與氧化酶,且無運動性。 (3)於好氧與厭氧環境均能生長,最適宜的生長溫度為37±1℃,屬於兼性發酵性菌株,葡萄糖代謝時不產生氣體。 |
乾酪乳酸桿菌 Lactobacillus caseiCS-773菌株 | (1)短桿狀或長桿狀多形性桿菌,長短不一,一般寬度均小於1.5μm。 (2)菌體兩端平齊呈方形,排列方式多為短鏈或長鏈;有時亦可見到球形菌。 (3)革蘭氏染色陽性,無運動性,不產芽胞。 |
長雙歧桿菌嬰兒亞種 Bifidobacterium longum subsp. InfantisBLI-02菌株 | (1)於MRS瓊脂生長呈短桿狀,尾端呈橢圓形,通常單獨或呈短鏈狀成對出現。 (2)革蘭氏染色陽性,不產孢子,不具觸酶與氧化酶,無運動性。 (3)於好氧與厭氧環境均能生長,最適宜的生長溫度為37±1℃,屬於兼性異質發酵性菌株,葡萄糖代謝時不產生氣體。 |
鼠李糖乳酸桿菌 Lactobacillus rhamnosusbv-77菌株 | (1)於MRS瓊脂生長呈Y字型、V字型或彎曲型不規則型態,菌體小且通常單獨出現不呈鏈狀。 (2)革蘭氏染色陽性,不產孢子,不具觸酶與氧化酶,無運動性。 (3)於絕對厭氧環境生長,最適宜的生長溫度為37±1℃,屬於兼性異質發酵性菌株,葡萄糖代謝時不產生氣體。 |
乳酸乳球菌 Lactococcus lactisLY-66菌株 | (1)革蘭氏染色陽性,廣泛應用於生產酪乳與奶酪。 (2)呈成對和短鏈成團的球菌,且根據生長條件不同,其卵圓形的典型長度0.5至1.5µm。 (3)不產生孢子,也不活動,可進行同型代謝而自糖產生L-(+)-乳酸。 (4)好氧性,且於M17培養基以37±1℃條件下培養。 |
<實施例2:菌株培養與投予>
菌株均以20%甘油存放於-80℃。使用前,須以含0.05%半胱氨酸的MRS培養液(DIFCO)37℃下活化24小時二次。菌株投予60公斤人體的每日劑量建議為2x10
10CFU/day,故人體每日每公斤體重的投予劑量為3.33x10
8CFU/kg/day。參照2005年美國食品藥物管理局制定的Estimating the Maximum Safe Starting Dose in Initial Clinical. Trials for Therapeutics in Adult Healthy Volunteers,人體與小鼠的劑量換算係數為12.3,可計算得到小鼠每日每公斤體重的投予劑量為4.1x10
9CFU/kg/day。於本文實施例,使用的小鼠體重30克,故小鼠每日的投予劑量為1.23x10
8CFU/day。於本文實施例,餵食安排於每日上午9點,並以PBS將菌落數稀釋至4.1x10
8CFU/mL後,餵食小鼠0.3mL含菌的PBS。此外,同時以0.3mL的PBS餵食對照小鼠。
<實施例3:體重與體脂肪測量>
本實施例連續餵食小鼠10週後評估小鼠下列參數:(1)體重:定期秤重,並比較實驗開始與結束的體重;(2)體脂肪:結束時取小鼠腎臟周圍、腸繫膜周圍與睪丸周圍的脂肪組織並秤重。
圖1比較著連續餵食不同飲食10週後的小鼠體重。相較於連續餵食正常脂肪飼料後(正常飲食組),小鼠體重於連續餵食高脂肪飼料後(高脂飲食組)有明顯增加(高脂飲食組:48.7±5.9g,正常飲食組:34.9±1.6g)。此外,相較於連續餵食高脂肪飼料後,小鼠體重無論於連續餵食高脂肪飼料與益生菌TYCA06菌株(高脂飲食+TYCA06組)、PL-02菌株(高脂飲食+PL-02組)、BLI-02菌株(高脂飲食+BLI-02組)、CS-773菌株(高脂飲食+CS-773組)、或bv-77菌株(高脂飲食+bv-77組)後均下降約11克。上述結果表示補充TYCA06菌株、PL-02菌株、BLI-02菌株、CS-773菌株、或bv-77菌株可降低高脂飲食造成的體重升高現象。
圖2比較著連續餵食不同飲食10週後的小鼠體脂肪重量。依「健康食品之不易形成體脂肪功能評估方法」,將副睪、腎臟、與腸繫膜周圍的脂肪總重量視為體脂肪重量。相較於連續餵食正常脂肪飼料後(正常飲食組),小鼠體脂肪重量於連續餵食高脂肪飼料後(高脂飲食組)有明顯增加(高脂飲食組:12.22±5.57g,正常飲食組:2.34±0.61g)。接著,相較於連續餵食高脂肪飼料後,小鼠體脂肪重量無論於連續餵食高脂肪飼料與益生菌TYCA06菌株(高脂飲食+TYCA06組)、PL-02菌株(高脂飲食+PL-02組)、BLI-02菌株(高脂飲食+BLI-02組)、CS-773菌株(高脂飲食+CS-773組)、或bv-77菌株(高脂飲食+bv-77組)後均有顯著降低。上述結果表示補充TYCA06菌株、PL-02菌株、BLI-02菌株、CS-773菌株、或bv-77菌株可降低高脂飲食造成的體脂肪提升現象。
圖3比較著連續餵食不同飲食10週後的小鼠副睪脂肪重量。相較於連續餵食正常脂肪飼料後(正常飲食組),小鼠副睪脂肪重量於連續餵食高脂肪飼料後(高脂飲食組)有明顯增加(高脂飲食組:3.06±0.2g,正常飲食組:0.35±0.1g)。接著,相較於連續餵食高脂肪飼料後,小鼠副睪脂肪重量無論於連續餵食高脂肪飼料與益生菌TYCA06菌株(高脂飲食+TYCA06組)、PL-02菌株(高脂飲食+PL-02組)、BLI-02菌株(高脂飲食+BLI-02組)、CS-773菌株(高脂飲食+CS-773組)、或bv-77菌株(高脂飲食+bv-77組)後均有顯著降低。上述結果表示補充TYCA06菌株、PL-02菌株、BLI-02菌株、CS-773菌株、或bv-77菌株可降低高脂飲食造成的內臟脂肪增加現象。
<實施例4:血液生化數值分析>
本實施例連續餵食小鼠10週後採集血液2mL,並利用生化分析儀分析血液總膽固醇含量、三酸甘油酯含量、與低密度脂蛋白含量等生化指標。
圖4比較著連續餵食不同飲食10週後的小鼠血液總膽固醇含量。相較於連續餵食正常脂肪飼料後(正常飲食組),小鼠血液總膽固醇含量於連續餵食高脂肪飼料後(高脂飲食組)有明顯增加(高脂飲食組:262±18mg/dL,正常飲食組:151±11mg/dL)。接著,相較於連續餵食高脂肪飼料後,小鼠血液總膽固醇含量無論於連續餵食高脂肪飼料與益生菌TYCA06菌株(高脂飲食+TYCA06組)、PL-02菌株(高脂飲食+PL-02組)、BLI-02菌株(高脂飲食+BLI-02組)、或CS-773菌株(高脂飲食+CS-773組)後約有顯著降低。上述結果表示補充TYCA06菌株、PL-02菌株、BLI-02菌株、或CS-773菌株可降低高脂飲食造成的高膽固醇現象。
圖5比較著連續餵食不同飲食10週後的小鼠血液三酸甘油酯含量。相較於連續餵食正常脂肪飼料後(正常飲食組),小鼠血液三酸甘油酯含量於連續餵食高脂肪飼料後(高脂飲食組)有明顯增加(高脂飲食組:93±11mg/dL,正常飲食組:57±9mg/dL)。接著,相較於連續餵食高脂肪飼料後,小鼠血液三酸甘油酯含量無論於連續餵食高脂肪飼料與益生菌TYCA06菌株(高脂飲食+TYCA06組)、PL-02菌株(高脂飲食+PL-02組)、BLI-02菌株(高脂飲食+BLI-02組)、CS-773菌株(高脂飲食+CS-773組)、或bv-77菌株(高脂飲食+bv-77組)後有顯著降低。上述結果表示補充TYCA06菌株、PL-02菌株、BLI-02菌株、CS-773菌株、或bv-77菌株可降低高脂飲食造成的高三酸甘油酯現象。
圖6比較著連續餵食不同飲食10週後的小鼠血液低密度脂蛋白含量。相較於連續餵食正常脂肪飼料後(正常飲食組),小鼠血液低密度脂蛋白含量於連續餵食高脂肪飼料後(高脂飲食組)有明顯增加(高脂飲食組:74.6±7.3mg/dL,正常飲食組:17.5±2.9mg/dL)。接著,相較於連續餵食高脂肪飼料後,小鼠血液低密度脂蛋白含量無論於連續餵食高脂肪飼料與益生菌TYCA06菌株(高脂飲食+TYCA06組)、PL-02菌株(高脂飲食+PL-02組)、BLI-02菌株(高脂飲食+BLI-02組)、CS-773菌株(高脂飲食+CS-773組)、或bv-77菌株(高脂飲食+bv-77組)後均有顯著降低。於未提供的圖式中,於連續餵食高脂肪飼料與市售益生菌LGG菌株後的低密度脂蛋白含量為54.9±6.6mg/dL,高於高脂飲食+TYCA06組、高脂飲食+PL-02組、高脂飲食+BLI-02組、高脂飲食+CS-773組、及高脂飲食+bv-77組。上述結果表示補充TYCA06菌株、PL-02菌株、BLI-02菌株、CS-773菌株、或bv-77菌株可降低高脂飲食造成的高低密度脂蛋白現象。
<實施例5:動物前肢抓力測試>
本實施例連續餵食小鼠4週後使用動物前肢抓力測量裝置對小鼠進行30分鐘前肢抓力測試以了解餵食對小鼠肌力表現的影響。前肢抓力測試如圖7所示,詳細過程請參照Nutrients. 2014 Jul 18;6(7):2681-96、Molecules. 2013 Apr 19;18(4):4689-702、Molecules. 2014 Mar 3;19(3):2793-807等。抓力值會受動物體重影響,為避免此情況於此以小鼠相對抓力表示抓力表現,相對抓力的計算如下:
。
圖8比較著連續餵食不同飲食4週後的小鼠抓力表現。於連續餵食正常脂肪飼料後(正常飲食組),相對抓力為343±14%;於連續餵食高脂肪飼料後(高脂飲食組),相對抓力為280±8%;於連續餵食高脂肪飼料與市售益生菌TWK10菌株後(高脂飲食+TWK10組),相對抓力為369±34%;於連續餵食高脂肪飼料與市售益生菌LGG菌株後(高脂飲食+LGG組),相對抓力為346±40%;於連續餵食高脂肪飼料與益生菌BLI-02菌株後(高脂飲食+BLI-02組),相對抓力為371±20%;於連續餵食高脂肪飼料與益生菌PL-02菌株後(高脂飲食+PL-02組),相對抓力為400±19%;於連續餵食高脂肪飼料與益生菌TYCA06菌株後(高脂飲食+TYCA06組),相對抓力為378±24%;於連續餵食高脂肪飼料與益生菌LY-66菌株後(高脂飲食+LY-66組),相對抓力為403±43%;於連續餵食高脂肪飼料與益生菌CS-773菌株後(高脂飲食+CS-773組),相對抓力為428±17%。上述結果表示補充BLI-02菌株、PL-02菌株、TYCA06菌株、LY-66菌株、或CS-773菌株可提高小鼠的運動抓力表現。
<實施例6:動物竭跑測試>
本實施例連續餵食小鼠4週後測試小鼠的耐力表現。依「健康食品之抗疲勞功能評估方法」,自測試前1週每次餵食後30分鐘讓小鼠適應跑步機(MK680C,Muromachi Kikai Co. Ltd)訓練。測試參考J Gerontol A Biol Sci Med Sci. 2009 Sep;64(9):940-8,以起始速度10m/min、5%坡度進行5分鐘,之後每分鐘提升2m/min的速度直至小鼠多次落入電擊區或於電擊區5秒內無法繼續前進,始判為「力竭」。
圖9比較著連續餵食不同飲食4週後的小鼠跑步力竭時間。於連續餵食正常脂肪飼料後(正常飲食組),力竭時間為11±3min;於連續餵食高脂肪飼料後(高脂飲食組),力竭時間為11±1min;於連續餵食高脂肪飼料與市售益生菌TWK10菌株後(高脂飲食+TWK10組),力竭時間為13±1min;於連續餵食高脂肪飼料與益生菌BLI-02菌株後(高脂飲食+BLI-02組),力竭時間為16±2min;於連續餵食高脂肪飼料與益生菌PL-02菌株後(高脂飲食+PL-02組),力竭時間為17±3min;於連續餵食高脂肪飼料與益生菌TYCA06菌株後(高脂飲食+TYCA06組),力竭時間為16±2min;於連續餵食高脂肪飼料與益生菌LY-66菌株後(高脂飲食+LY-66組),力竭時間為16±1min;於連續餵食高脂肪飼料與益生菌CS-773菌株後(高脂飲食+CS-773組),力竭時間為16±2min。上述結果表示補充BLI-02菌株、PL-02菌株、TYCA06菌株、LY-66菌株、或CS-773菌株可提高小鼠的運動耐力表現。
<實施例7:肌肉細胞抗氧化試驗>
文獻指出肌肉具備高抗氧化能力下有助於排除氧化因子,進而降低肌肉疲勞。本實施例測試益生菌對肌肉細胞抗氧化能力的影響。
先以每孔2x10
6個細胞密度種植小鼠成肌細胞C2C12於培養皿,並於DMEM培養液(含10% FBS、1% Penicillin/Streptomycin、0.01mg/mL human transferrin)內培養3天後,以新的DMEM培養液(含5% FBS)替換。另於益生菌活化18小時後,以DMEM培養液(含2% BSA、500μM油酸)調整菌落數至2x10
8CFU/mL。接著,取2mL菌液與小鼠成肌細胞C2C12於37℃恆溫培養箱內共培養12小時。移除培養液後,每孔加入lysis buffer(pH7.0,含1mM EDTA、50mM磷酸鉀)破碎細胞,並於4℃以轉速10,000rpm,離心15分鐘分離取得上清液。最後,分析所得的上清液以取得胞內過氧化氫酶(catalase)活性。
如圖10所示,未處理與維他命C處理後的活性均為19nmol/min/mL;CS-773菌株處理後的活性為28nmol/min/mL,TYCA06菌株處理後的活性為26nmol/min/mL,PL-02菌株處理後的活性為26nmol/min/mL。這表示補充CS-773菌株、TYCA06菌株、或PL-02菌株均可提升肌肉抗氧化能力進而降低疲勞。
另發現CS-773菌株、TYCA06菌株、及PL-02菌株(菌落數比1:1:1,總菌落數4x10
8CFU)共處理後的活性為81nmol/min/mL,遠大於CS-773菌株單獨處理後之活性、TYCA06菌株單獨處理後之活性、與PL-02菌株單獨處理後之活性的總和。這表示共同補充CS-773菌株、TYCA06菌株、及PL-02菌株對肌肉抗氧化能力的提升具協同效應。
<實施例8:抗吸附脂肪酸試驗>
益生菌能維持人體腸胃道健康,也包含食物分解與利用。油酸為食物中含量最多的脂肪酸,文獻報導
Lactobacillus會將棕梠酸作為細胞膜原料之一來合成環丙烯脂肪酸,進而有助菌體抵抗腸胃道的酸性環境,提高菌體存活。因此,益生菌可藉由與腸道細胞競爭油酸來減少腸道的脂肪吸收。本實施例測試益生菌對腸道細胞吸附脂肪的影響。
先以每孔2x10
6個細胞密度種植人類結腸癌細胞Caco-2於培養皿,並於DMEM培養液(含10% FBS、1% Penicillin/Streptomycin、0.01mg/mL human transferrin)內培養3天後,以新的DMEM培養液(含5% FBS)替換。另於益生菌活化18小時後,以DMEM培養液(含2% BSA、500μM油酸)調整菌落數至2x10
8CFU/mL。接著,取2mL菌液、500μM油酸與人類結腸癌細胞Caco-2於37℃恆溫培養箱內共培養6小時。最後,採用油紅O染色測定OD520nm值以分析胞內脂肪含量。
如圖11所示,以僅油酸處理後的胞內脂肪含量定為100%;CS-773菌株處理後的相對含量為92%,TYCA06菌株處理後的相對含量為89%,PL-02菌株處理後的相對含量為87.21%。這表示CS-773菌株、TYCA06菌株、或PL-02菌株均可與人類結腸癌細胞Caco-2競爭油酸,使胞內累績的油酸含量降低,間接證實補充CS-773菌株、TYCA06菌株、或PL-02菌株均可降低細胞吸收脂肪。另發現CS-773菌株、TYCA06菌株、及PL-02菌株(菌落數比1:1:1,總菌落數4x10
8CFU)共處理後的相對含量為73%,可知共同補充CS-773菌株、TYCA06菌株、及PL-02菌株對細胞吸收脂肪的降低具協同效應。
綜上所述,以人體建議每日2x10
10CFU總劑量單獨或共同補充本發明的PL-02菌株、TYCA06菌株、及CS-773菌株能顯著提升肌力與增加運動耐力。須說明的是,僅發現少數乳酸菌菌株具備可改善身體疲勞與提升運動表現的功效,並進一步地於動物體內(
in vivo)實驗獲得證實。此外,乳酸菌對身體健康的功能在於菌株(strains)特異性,而非菌種(species)。對於人體健康有特殊功效的菌株稱作「功能性益生菌」(Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food, London, Ontario, Canada, April 30 and May 1, 2002)。
惟以上所述者,僅為本發明之較佳實施例,但不能以此限定本發明實施之範圍;故,凡依本發明申請專利範圍及發明說明書內容所作之簡單的等效改變與修飾,皆仍屬本發明專利涵蓋之範圍內。
無
圖1為一長條圖,說明連續餵食不同飲食10週後之小鼠體重的差異;
圖2為一長條圖,說明連續餵食不同飲食10週後之小鼠體脂肪重量的差異;
圖3為一長條圖,說明連續餵食不同飲食10週後之小鼠副睪脂肪重量的差異;
圖4為一長條圖,說明連續餵食不同飲食10週後之小鼠血液總膽固醇含量的差異;
圖5為一長條圖,說明連續餵食不同飲食10週後之小鼠血液三酸甘油酯含量的差異;
圖6為一長條圖,說明連續餵食不同飲食10週後之小鼠血液低密度脂蛋白含量的差異;
圖7為一照片圖,示意小鼠前肢抓力測試;
圖8為一長條圖,說明連續餵食不同飲食4週後之小鼠抓力表現的差異;
圖9為一長條圖,說明連續餵食不同飲食4週後之小鼠跑步力竭時間的差異;
圖10為一長條圖,說明益生菌對小鼠成肌細胞C2C12抗氧化能力的影響;以及
圖11為一長條圖,說明益生菌對人類結腸癌細胞Caco-2吸附脂肪的影響。
1、TW中華民國 食品工業發展研究所生物資源保存及研究中心 2020/07/28 BCRC 911012;
2、TW中華民國 食品工業發展研究所生物資源保存及研究中心 2018/01/18 BCRC 910813;
3、TW中華民國 食品工業發展研究所生物資源保存及研究中心 2011/12/27 BCRC 910534;
4、TW中華民國 食品工業發展研究所生物資源保存及研究中心 2018/01/18 BCRC 910812;
5、TW中華民國 食品工業發展研究所生物資源保存及研究中心 2011/12/27 BCRC 910533;以及
6、TW中華民國 食品工業發展研究所生物資源保存及研究中心 2021/04/23 BCRC 911055。
Claims (12)
- 一種乳酸菌組合物,係包括: 植物乳桿菌 Lactobacillus plantarumPL-02菌株(寄存編號:BCRC 911012); 嗜酸乳酸桿菌 Lactobacillus acidophilusTYCA06菌株(寄存編號:BCRC 910813); 乾酪乳酸桿菌 Lactobacillus caseiCS-773菌株(寄存編號:BCRC 910534);以及 生理上可接受的賦形劑、稀釋劑或載體; 其中該PL-02菌株、該TYCA06菌株與該CS-773菌株均寄存於財團法人食品工業發展研究所生物資源保存及研究中心。
- 如請求項1所述之乳酸菌組合物,更包括: 長雙歧桿菌嬰兒亞種 Bifidobacterium longum subsp. infantisBLI-02菌株(寄存編號:BCRC 910812);以及 鼠李糖乳酸桿菌 Lactobacillus rhamnosusbv-77菌株(寄存編號:BCRC 910533); 其中該BLI-02菌株與該bv-77菌株均寄存於財團法人食品工業發展研究所生物資源保存及研究中心。
- 如請求項1所述之乳酸菌組合物,更包括: 長雙歧桿菌嬰兒亞種 Bifidobacterium longum subsp. infantisBLI-02菌株(寄存編號:BCRC 910812);以及 乳酸乳球菌 Lactococcus lactisLY-66菌株(寄存編號:BCRC 911055); 其中該BLI-02菌株與該LY-66菌株均寄存於財團法人食品工業發展研究所生物資源保存及研究中心。
- 如請求項1所述之乳酸菌組合物,係一食品組合物或一醫藥組合物。
- 如請求項1所述之乳酸菌組合物,係一食品組合物,其中該生理上可接受的賦形劑、稀釋劑或載體為一食品,該食品為乳製飲品、茶、咖啡、糖果或機能性飲品,該乳製飲品為發酵乳、優格、乳酪或乳粉。
- 如請求項1所述之乳酸菌組合物,係一醫藥組合物,其中該醫藥組合物呈口服劑型,而該口服劑型為錠劑、膠囊、溶液劑或粉劑。
- 如請求項1至3中任一所述之乳酸菌組合物,其總菌株數量為10 6CFU以上。
- 一種如請求項1至3中任一所述之乳酸菌組合物用於製備減少脂肪與提升運動表現的組合物的用途。
- 如請求項8所述之用途,其中該減少脂肪與提升運動表現的組合物係一食品組合物或一醫藥組合物。
- 如請求項8所述之用途,其中該減少脂肪與提升運動表現的組合物係一食品組合物,該生理上可接受的賦形劑、稀釋劑或載體為一食品,該食品為乳製飲品、茶、咖啡、糖果或機能性飲品,該乳製飲品為發酵乳、優格、乳酪或乳粉。
- 如請求項8所述之用途,其中該減少脂肪與提升運動表現的組合物係一醫藥組合物,其中該醫藥組合物呈口服劑型,而該口服劑型為錠劑、膠囊、溶液劑或粉劑。
- 如請求項8所述之用途,其中該乳酸菌組合物的總菌株數量為10 6CFU以上。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110467618.9A CN115247138B (zh) | 2021-04-28 | 2021-04-28 | 具减少脂肪与提升运动表现的乳酸菌组合物及其用途 |
CN202110467618.9 | 2021-04-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
TWI782550B TWI782550B (zh) | 2022-11-01 |
TW202242090A true TW202242090A (zh) | 2022-11-01 |
Family
ID=83696031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW110119591A TWI782550B (zh) | 2021-04-28 | 2021-05-28 | 具減少脂肪與提升運動表現的乳酸菌組合物及其用途 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11779615B2 (zh) |
CN (1) | CN115247138B (zh) |
TW (1) | TWI782550B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115873761A (zh) * | 2022-11-10 | 2023-03-31 | 重庆第二师范学院 | 一种植物乳杆菌ksfy01及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI572713B (zh) * | 2014-10-31 | 2017-03-01 | 豐華生物科技股份有限公司 | 抗肥胖之乳酸菌菌株及其於食品組成物以及醫藥組成物之應用 |
CA2997680A1 (en) * | 2015-10-02 | 2017-04-06 | Balchem Corporation | Composition for improved performance |
US10792317B2 (en) * | 2016-08-24 | 2020-10-06 | Synbio Tech Inc. | Method for reducing body fat by administering Lactobacillus plantarum |
TWI701034B (zh) * | 2018-05-28 | 2020-08-11 | 豐華生物科技股份有限公司 | 用於改善腎病及抑制發炎之乳酸菌菌株的醫藥組合物及食品組合物 |
JP7130287B2 (ja) * | 2018-12-12 | 2022-09-05 | 生合生物科技股▲ふん▼有限公司 | プロバイオティクス組成物の製造方法 |
TWI737987B (zh) * | 2019-04-23 | 2021-09-01 | 豐華生物科技股份有限公司 | 一種乳酸菌菌株在製備提升運動能力與抗疲勞之組合物之用途 |
TW202102120A (zh) * | 2019-07-12 | 2021-01-16 | 錢佑 | 具抗氧化與抑制前列腺癌細胞生長的半固態優格及其製備方法 |
CN112410241A (zh) * | 2019-08-22 | 2021-02-26 | 丰华生物科技股份有限公司 | 用以抗氧化的含乳酸菌菌株或其发酵物的组合物及其用途 |
CN111254089B (zh) * | 2019-12-30 | 2022-01-18 | 杭州娃哈哈科技有限公司 | 一株具有减肥功能的植物乳杆菌及其应用 |
-
2021
- 2021-04-28 CN CN202110467618.9A patent/CN115247138B/zh active Active
- 2021-05-28 TW TW110119591A patent/TWI782550B/zh active
- 2021-07-19 US US17/378,955 patent/US11779615B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11779615B2 (en) | 2023-10-10 |
CN115247138B (zh) | 2023-05-26 |
CN115247138A (zh) | 2022-10-28 |
US20220347238A1 (en) | 2022-11-03 |
TWI782550B (zh) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5718916B2 (ja) | 新規なラクトバチルス・プランタラム及びこれを含む組成物 | |
US9113641B2 (en) | Probiotic bacteria and regulation of fat storage | |
DK2478910T3 (en) | ANTI-ADIPOSITY AGENT, ANTI-ADIPOSITA NUTRITION OR DRINK, GLUCOSE TOLERANCE EFFECTIVE AGENT, AND NUTRITION OR DRINK FOR IMPROVING GLUCOSE TOLERANCE | |
JP6197045B2 (ja) | ビフィドバクテリウム・アニマリスssp.アニマリスの株 | |
US20140322186A1 (en) | Agent for prevention or amelioration of obesity | |
TWI739495B (zh) | 可促進排便的組合物及其用途 | |
JP7193469B2 (ja) | 筋肉増量用組成物 | |
JP6923883B2 (ja) | 栄養状態改善に使用するための組成物 | |
US8765118B2 (en) | Lactococcus lactis strain with high vitamin K2 production | |
CN115039883A (zh) | 使用植物乳杆菌tsp05分离株来降低嘌呤含量以及尿酸水平 | |
JP2013537427A (ja) | ビタミンk2高生産性ラクトコッカス・ラクティス株 | |
US20130309212A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
JP2023033532A (ja) | 骨格筋遅筋化用組成物 | |
JP5816273B2 (ja) | 経上皮抵抗の改善に用いるためのプロバイオティクス株 | |
TWI782550B (zh) | 具減少脂肪與提升運動表現的乳酸菌組合物及其用途 | |
CN113528367A (zh) | 一株具有预防腹泻和降解胆固醇功能的凝结芽孢杆菌 | |
EP3479836B1 (en) | Cartilage regeneration facilitating composition | |
KR101809616B1 (ko) | 항비만효과를 가지는 케피어 유래 프로바이오틱 균주 | |
JP6061842B2 (ja) | Qol改善又は持続剤 | |
Khagwal et al. | Isolation and characterization of potential probiotic strains isolated from traditional Indian fermented foods | |
JP2004018469A (ja) | 抗アレルギー剤 | |
CN115948296B (zh) | 用于改善肌骨健康和/或提高运动能力的植物乳杆菌及其组合物与应用 | |
KR20240066540A (ko) | 지방합성 억제 효능을 갖는 신규 유산균 락토바실러스 플란타룸 빈스플로라 1712 균주 및 이를 유효성분으로 함유하는 제품 | |
KR20220109662A (ko) | 근감소증 예방 또는 개선 효과를 갖는 바실러스 벨레젠시스 및 이의 용도 | |
CN116555103A (zh) | 一种具有改善骨密度和增强免疫力功能的动物双歧杆菌br008及其应用 |